Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the target of a large drop in short interest in January. As of January 15th, there was short interest totaling 4,183,761 shares, a drop of 27.3% from the December 31st total of 5,752,164 shares. Approximately 7.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 723,298 shares, the days-to-cover ratio is presently 5.8 days. Based on an average daily trading volume, of 723,298 shares, the days-to-cover ratio is presently 5.8 days. Approximately 7.7% of the shares of the stock are sold short.

Astria Therapeutics Trading Up 0.6%

Shares of NASDAQ:ATXS opened at $12.58 on Friday. The company has a market capitalization of $718.13 million, a price-to-earnings ratio of -5.88 and a beta of 0.01. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $13.29. The firm’s 50-day moving average is $12.77 and its 200 day moving average is $10.11.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The business had revenue of $0.71 million for the quarter, compared to analyst estimates of $10.67 million. As a group, equities analysts forecast that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Astria Therapeutics

Several hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its position in shares of Astria Therapeutics by 10,311.8% during the third quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 3,506 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Astria Therapeutics by 185.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,557 shares during the period. Brevan Howard Capital Management LP bought a new stake in Astria Therapeutics during the 3rd quarter valued at about $98,000. AXQ Capital LP purchased a new stake in Astria Therapeutics in the 3rd quarter valued at about $115,000. Finally, Bailard Inc. purchased a new stake in Astria Therapeutics in the 2nd quarter valued at about $142,000. Institutional investors own 98.98% of the company’s stock.

Wall Street Analyst Weigh In

ATXS has been the topic of several recent research reports. Citizens Jmp cut Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Astria Therapeutics in a research note on Wednesday, January 21st. Jefferies Financial Group cut shares of Astria Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $30.00 to $13.00 in a research note on Tuesday, October 14th. HC Wainwright cut shares of Astria Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 16th. Finally, Wedbush set a $13.00 price target on shares of Astria Therapeutics and gave the company a “neutral” rating in a report on Wednesday, October 15th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Astria Therapeutics presently has a consensus rating of “Hold” and an average target price of $24.50.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.